Active Pass Pharmaceuticals Announces the Appointment of Brett Gannon to Board.

VANCOUVER, British Columbia -- Active Pass Pharmaceuticals today announced the appointment of Brett Gannon to its Board of Directors. Mr. Gannon becomes an independent Director with Active Pass Pharmaceuticals and is also currently the CFO of Xillix Technologies Corp. He is a highly seasoned executive with more than 20 years of experience in corporate finance in Canada, the US and abroad. In his assignments, Mr Gannon has held many key corporate positions including CFO, Corporate Secretary, Director, Executive VP Finance, President and Chief Operating Officer. Mr. Gannon is also a member of the Canadian Institute of Chartered Accountants.

Dr. David MacDonald, President and CEO of Active Pass Pharmaceuticals commenting on the appointment, said, "We are very pleased to have a person with Mr. Gannon's qualifications and experience join our board. His expertise and guidance in financing will be particularly valuable as we continue to grow our business."

Active Pass is a privately held biotechnology company located in Vancouver, Canada. The company is focused on exploiting the ABC transporter gene family as pharmacological targets for the treatment of disease. The company's lead program is focused on inhibitors of the ABC transporter, CFTR, for the treatment of diarrhea and polycystic kidney disease. Active Pass was the recent recipient of a $ 2.8 M USD grant from the NIH to support development of their antidiarrheal program.